Acrylamide is a known neurotoxin in humans, and a carcinogen in animals ([@bib10]; [@bib20]; [@bib12]). In 1994, based on animals studies, as well as evidence found in humans, the International Agency for Research on Cancer (IARC) classified acrylamide as 'probably carcinogenic\' to humans (IARC group 2A; [@bib15]). In 2002, Swedish researchers discovered acrylamide in some heat-treated carbohydrate-rich foods ([@bib26]), and further research concluded that acrylamide is formed during common cooking procedures (predominantly through the Maillard reaction), such as frying, grilling, and baking ([@bib10]). In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, the main determinants of estimated dietary intake of acrylamide based on 24-h dietary recall (DR) were bread, crisp bread, rusks, coffee, fried potatoes, cakes, biscuits, and cookies ([@bib9]). Acrylamide is also a component of cigarette smoke, thus, smoking is an important source of exposure ([@bib3]; [@bib29]).

Acrylamide is metabolised via the Cyp2e1 enzyme system to glycidamide, a chemically reactive epoxide and mutagen in animals ([@bib6]; [@bib12]). After acrylamide administration, hormone-related (including uterine tumours) and other tumours (e.g., oral tissues) have been observed in rats ([@bib17]).

Endometrial cancer (EC) is the fourth most common cancer diagnosed in European women, but mortality is relatively low with a 5-year survival rate varying from 65 to 85% ([@bib5]; [@bib7]). There is considerable international variation in incidence as well as mortality, and both rates increase dramatically with age ([@bib5]; [@bib7]; [@bib16]). Established risks factors for EC are obesity, low physical activity, history of polycystic ovary syndrome, and greater lifetime exposure to estrogens ([@bib18]; [@bib5]). The use of oral contraceptives (OCs, containing both oestrogen and progestin in the formula) is well established to lower the risk of developing EC ([@bib5]; [@bib11]). There is evidence that tobacco smoking also reduces the risk of EC ([@bib28]; [@bib5]); however, an EPIC study reported an increased risk of EC in premenopausal women who smoked ([@bib1]). Endometrial cancer is generally classified into two types: type-I EC are mostly endometrioid adenocarcinomas and are associated with unopposed oestrogen exposure; and type-II EC tumours are mainly serous carcinomas, are believed to be oestrogen independent, and have poor prognosis ([@bib2]; [@bib24]).

Three prospective epidemiological studies have assessed the relationship between dietary intake of acrylamide and EC risk. The Netherlands Cohort Study (NLCS) observed a positive association between acrylamide intake and EC risk, especially in never smokers ([@bib14]). Likewise, the Nurses\' Health Study (NHS) reported an increased relative risk among women with the highest acrylamide intake ([@bib34]); however, no associations between acrylamide intake and EC were observed in the Swedish Mammography Cohort (SMC; [@bib19]).

The present study evaluated the association between questionnaire-based dietary intake of acrylamide and the risk of overall EC (type I, type II, and undefined) and type-I EC tumours, using data from 301 113 EPIC cohort participants. Subgroup analyses among never-smoking women and never users of OCs were performed with the aim to eliminate the influence of smoking (both a source of acrylamide and a protective factor) and the protective effect of OCs on EC risk.

Methods
=======

Study population
----------------

The EPIC study was initiated between 1992 and 1998 in 23 centres from 10 European countries with the aim to investigate the relationships between nutrition and lifestyle factors, and cancer and other chronic diseases. All participants gave written informed consent. Ethical review boards from the IARC and local centres participating in EPIC approved the study. The EPIC methodology has been reported in detail by [@bib22].

The EPIC study includes 521 330 participants, of which 367 903 are women. A total of 66 790 women were excluded from the current analyses because they were diagnosed with cancer before recruitment (*n*=19 853), had a hysterectomy (*n*=35 116), had incomplete follow-up data (*n*=2896), had no lifestyle or dietary information (*n*=2877), and no information on dietary intake of acrylamide at baseline (*n*=3), or had an extreme ratio of energy intake to energy required (*n*=6045); resulting in 301 113 participants for this analysis.

Identification of endometrial cancer cases
------------------------------------------

Information on cancer incidence was obtained through population cancer registries, or via a combination of methods: health insurance records, cancer and pathology registries, and active follow-up (France, Germany, Naples, and Greece). Subjects were followed until cancer diagnosis (except non-melanoma skin cancer), emigration, death, or until the end of follow-up (dates varied between centres, from December 2004 to June 2010).

Tumour morphology was specified for 664 (48%) cases, of which 627 (93%) were classified as type I (endometrioid adenocarcinomas), and 37 (7%) as type II (serous, or clear cell, or squamous adenocarcinomas; [@bib27]). Overall EC comprises type I, type II, and cases that were undefined for histology. Tumours were classified as C54 according to the International Classification of Diseases, 10th revision.

Dietary and acrylamide intake assessment
----------------------------------------

Information on diet was assessed at baseline (with timeframe referring to the previous 12 months) through country-specific, validated dietary questionnaires (DQ; [@bib22]). The development of the acrylamide database in EPIC has been previously described ([@bib9]; [@bib21]). To summarise, the EPIC acrylamide database is a compilation of the information acquired to a large extent from the European Community Institute for Reference Materials and Measurements (IRMM). The average acrylamide levels for specific foods in the IRMM database were obtained through a combination of methods based on either liquid or gas chromatography coupled to mass spectrometry. All food items with acrylamide data derived from the IRMM database were classified according to EPIC-Soft food classification ([@bib30]; [@bib25]). The reported foods on the DQ and, when available, their relevant description (e.g., baked potatoes) were matched with the corresponding foods in the acrylamide database. Information on cooking methods for acrylamide sources was available for potatoes (except in Italy), bread, and breaded meats. If an exact match was not possible, the food was linked to the mean of all foods of the respective food group in the acrylamide database ([@bib9]; [@bib21]).

Lifestyle and reproductive information assessment
-------------------------------------------------

At baseline, questionnaires were used to collect data on tobacco smoking, education, physical activity, and menstrual and reproductive factors (i.e., age at first menstrual period, ever use of OCs, ever use of hormone replacement therapy (HRT)). Baseline menopausal status was self-reported for each woman in most centres, and in case of incomplete data, an algorithm was developed based on the age at recruitment: women were classified as premenopausal if their baseline ages were \<46 years, or reported having menstrual cycles the year before recruitment; perimenopausal if their ages were between 46 and 55 years, or had irregular menses the year before recruitment; and postmenopausal if their ages were \>56 years, or had bilateral ovariectomy (surgical menopause), or had \<4 menstrual cycles in the past year before recruitment ([@bib22]).

Height, weight, and waist or hip circumference were measured at baseline by trained personnel for all EPIC participants, except for most participants in France, Norway and Oxford cohorts, where height and weight were self-reported. Umeå and Norway did not record data on waist or hip circumference, and only some participants from France have information on waist (29%) and hip circumference (29% [@bib22]).

Statistical analysis
--------------------

Proportional hazards models (Cox regression) were used to estimate hazards ratio (HR) and 95% confidence intervals (95% CI) for overall EC risk in relation to dietary intake of acrylamide. Analyses were also performed separately for risk of type-I EC. Analyses for type-II EC cases were not carried out due to small sample sizes (*n*=37). All multivariate models had age as the time scale and were stratified by study centre to control for centre effects (i.e., questionnaire design and follow-up procedures), and by age at recruitment (in 1-year categories) as the primary time variable.

All estimates of acrylamide intake in these analyses were energy adjusted using the residual method ([@bib32]; [@bib8]). One continuous variable and one categorical variable for dietary intake of acrylamide were evaluated in Cox models: average daily intake in 10 *μ*g increments (10 *μ*g per day), and quintiles of intake (*μ*g per day) based on the distribution in the full EPIC cohort of women.

The following variables were included as known risk factors or potential confounders in these analyses: body mass index (BMI, kg m^−2^), smoking status (never smokers, current pipe or cigar or occasional smokers, current cigarette smokers: 1--15, 16--25, or ⩾26 cigarettes per day, former cigarette smokers who quit \>20 years, 11--20 years, or ⩽10 years before recruitment), history of diabetes (no, yes), OC use (never, ever), HRT use (never, ever), baseline menopause status combined with age at menopause (premenopausal, perimenopausal, postmenopausal with: \<45, 45--49, 50--52, 53--55, and ⩾56 years, surgical menopause, postmenopausal women with missing age at menopause), parity (nulliparous, 1, 2, ⩾3, parous but with missing number of full-term pregnancies), and age at menarche (\<12, 12, 13, 14, and ⩾15 years). Variables for education level (none, primary, technical/professional, secondary, and higher education), physical activity using the Cambridge index ([@bib31]), alcohol intake (non-drinkers, drinkers of 0--6, \>6--12, \>12--24, and \>24 g per day), total fat (g per day), total fibre (g per day), vegetables (g per day), and fruits, nuts and seeds consumption (g per day) were evaluated, but were not included in final models because they did not change effect estimates \>10%. Missing values for specific variables were categorised as 'unknown\' and were included in the analyses. All statistical models presented in this study were further adjusted for total energy intake (per 1000 kcal per day).

Analyses of effect-measure modification were carried out by known EC risk factors (BMI, menopausal status, and HRT use), by known protective factors (OC use, and smoking status), by geographical region, and by factors that may affect the activity of Cyp2e1 (alcohol intake, and BMI; [@bib33]; [@bib9]). The following subgroups were examined: BMI (\<25 kg m^−2^, ⩾25 kg m^−2^), OC use (never, ever), HRT use (never, ever), baseline menopausal status (premenopausal, perimenopausal, and postmenopausal), smoking status (never, current, or former smokers), and alcohol intake (never, ever drinkers). For region-specific analyses, countries were classified as northern (France, UK, The Netherlands, Germany, Sweden, Denmark, and Norway) and southern (Italy, Spain, and Greece); and by median acrylamide-intake level ('high\' ⩾21 *μ*g per day and 'low\' \<21 *μ*g per day) in the EPIC cohort.

Sensitivity analyses were additionally performed excluding all cases diagnosed during the first 2 years of follow-up, with the aim to avoid possible influences of preclinical disease on dietary habits including intakes of acrylamide.

To evaluate dose-response trends, the median value for each acrylamide quintile was estimated and included in a score test. Statistical significance of effect-measure modification was evaluated using a LRT and based on the continuous acrylamide intake variable. The proportional hazards (PHs) assumption was tested in STATA (College Station, Texas, USA) using Schoenfeld residuals ([@bib23]), and it was met for type-I EC analyses; however, it was violated for overall EC analyses. Variables responsible for the PH violation were: OC use, HRT use, and smoking status; thus, stratified analyses by these variables were also performed for overall EC risk, and the PH assumption was subsequently met. All analyses were performed using SAS v. 9.1 (Cary, NC, USA).

Results
=======

Basic information on cohorts members
------------------------------------

The average acrylamide intake in the EPIC subcohort of women was 24±13 *μ*g per day (0.4±0.2 *μ*g per kg body weight per day), and the 10th--90th percentile range was 10--41 *μ*g per day (0.2--0.6 *μ*g per kg body weight per day). Denmark, followed by the UK and The Netherlands, had the highest mean and median dietary acrylamide intakes, while Italy had the lowest acrylamide intake ([Table 1](#tbl1){ref-type="table"}). In total, after 11 years of follow-up there were 1382 first primary EC cases, of which 627 were classified as type-I EC, 37 type-II EC, and 718 cases that were not specified with regard to histology ([Table 1](#tbl1){ref-type="table"}).

Women with the highest acrylamide-intake levels tended to have the highest intakes of energy, total fats, total carbohydrates, vegetables, and coffee. Women with the highest intake levels tended to be premenopausal, have a higher proportion of OC use and with longer duration, and were more often current smokers or former smokers at baseline ([Table 2](#tbl2){ref-type="table"}). In contrast, women classified in the lower quintiles tended to be postmenopausal, non-consumers of alcohol and tobacco, and to have lower levels of physical activity ([Table 2](#tbl2){ref-type="table"}). There were few differences across acrylamide intake quintiles by age, age at first menstrual period, age at menopause, BMI, or waist-to-hip ratio ([Table 2](#tbl2){ref-type="table"}).

Overall EC risk and type-I EC risk
----------------------------------

No association was observed between acrylamide intake and overall EC ([Table 3](#tbl3){ref-type="table"}) or type-I EC risk ([Table 4](#tbl4){ref-type="table"}). Similar results were found when we restricted the analyses to cases diagnosed 2 years after recruitment ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}), or when known type-I and type-II EC were combined in the same analysis (data not shown). Further, an analysis among EC cases that could not be classified into type-I or type-II EC was also carried out, but no associations were observed (data not shown). Most of the stratified analyses performed with overall EC (type I, type II, and undefined) cases indicated no heterogeneity between subgroups ([Table 3](#tbl3){ref-type="table"}). When stratified analyses by OC use, and by OC use and smoking were performed, statistically significant LRT *P-*values were observed; however, neither the continuous nor the categorical acrylamide variable suggested an association with disease risk ([Table 3](#tbl3){ref-type="table"}).

Effect-measure modification by OC use and smoking in type-I EC
--------------------------------------------------------------

Subgroup analyses for known type-I EC were also stratified by smoking status, OC use, menopausal status, HRT use, BMI, and geographical region. None of the HRs in never smokers or ever smokers indicated associations between dietary acrylamide intake and type-I EC risk; however, statistically significant evidence for heterogeneity was observed (LRT *P*-value: 0.01; [Table 4](#tbl4){ref-type="table"}).

Inverse associations were observed for the highest versus the lowest quintile of acrylamide intake (HR~Q5vsQ1~: 0.57, 95% CI: 0.34--0.96; *P*-value for trend: 0.01), as well as a continuous variable (HR: 0.83, 95% CI: 0.71--0.95; [Table 4](#tbl4){ref-type="table"}). Regarding the HRs obtained in the subgroup of non-OC users, none of them were statistically significant (HR~10~ ~*μ*g\ per\ day~: 1.10, 95% CI: 0.99--1.23; [Table 4](#tbl4){ref-type="table"}).

Moreover, the OC-use model was additionally adjusted by duration of OC use (per 2 years of OC use), and the results were similar to those presented without adjustment for this variable (data not shown).

There were some differences in non-dietary variables between OC users and non-users. OC users with the highest acrylamide intake tended to have a higher proportion of former or current smokers, and these women tended to smoke more cigarettes per day than non-users. Further, non-OC users were older than OC users, but with similar age at menopause. With regard to dietary factors, there were no major differences between OC users and non-users (data not shown).

The association between acrylamide intake and type-I EC risk among OC users and non-users was also evaluated by smoking status. Women who at baseline reported being never smokers and non-users of OCs (including 203 type-I EC cases) were at the highest risk of developing type-I EC, when acrylamide was evaluated both as a continuous variable and in quintiles (HR~10~ ~*μ*g\ per\ day~: 1.17, 95% CI: 1.02--1.34; HR~Q5vsQ1~: 1.97, 95% CI: 1.08--3.62; *P-*value for trend: 0.01; [Table 4](#tbl4){ref-type="table"}). Otherwise, associations between dietary acrylamide intake and type-I EC were below the null value in ever smokers (current and former smokers) and OC users (HR~10~ ~*μ*g\ per\ day~: 0.75, 95% CI: 0.60--0.94; [Table 4](#tbl4){ref-type="table"}). The LRT *P*-value of the contrast between 'never smokers/non-OC users\', 'ever smokers/non-OC users\', 'never smokers/OC users\', and 'ever smokers/OC users\' for the continuous acrylamide intake variable was 0.01 ([Table 4](#tbl4){ref-type="table"}).

Other effect-measure modifications in type-I EC
-----------------------------------------------

There was no evidence for effect-measure modification by BMI ([Table 4](#tbl4){ref-type="table"}), HRT use, or by geographical region (all LRT *P-*values \>0.12, data not shown); however, evidence for effect-measure modification was found when the analyses were stratified by baseline menopausal status (LRT *P-*value: 0.01; [Table 4](#tbl4){ref-type="table"}), but none of the individual HRs were statistically significant. Likewise, effect-measure modification was observed by alcohol intake (LRT *P-*value: 0.01), but only the continuous variable in never drinkers showed a statistically significant positive association (HR~10~ ~*μ*g\ per\ day~: 1.23, 95% CI: 1.02--1.47; [Table 4](#tbl4){ref-type="table"}).

Discussion
==========

No overall association was observed between dietary intake of acrylamide and overall EC or type-I EC risk; nevertheless, elevated relative risks, as well as *P*-values for linear trend were observed for the association between dietary intake of acrylamide and type-I EC among women who both never smoked and never used OCs. Statistically significant inverse associations between type-I EC risk and acrylamide intake were observed in OC users, and among OC users and ever smokers.

It is widely published that use of OCs (containing oestrogen and progestin) is protective against EC risk, and this effect is maintained for years ([@bib2]; [@bib5]; [@bib4]; [@bib11]). Likewise, cigarette smoking tends to lower the risk of developing EC, and it is thought to be more pronounced in recent smokers ([@bib5]). All the relative risk estimates for type-I EC risk observed among OC users and ever smokers were below the null value; however, because OC use, duration of OC use, and smoking are associated with higher acrylamide intake in EPIC, and are also associated with lower EC risk, residual confounding by these variables may play a role in the observed inverse associations (in OC users and smokers). In addition, OC users, compared to non-OC users, tended to smoke more cigarettes per day and reported less time since having quit smoking. Thus, these baseline characteristics may have partially influenced the results obtained in this subgroup of women. Moreover, it has been hypothesised that acrylamide may have hormonal effects, and the results in non-OC users for type I are potentially compatible with this hypothesis, since type-I EC is considered to be oestrogen driven ([@bib2]); nevertheless, this hypothesis has not been substantiated, and other mechanisms (i.e., genotoxicity caused by glycidamide) may be compatible with the results ([@bib12], [@bib13]).

The relation between dietary intake of acrylamide and EC risk has been previously published in three prospective cohort studies. Both the NLCS and NHS studies found statistically significantly increased relative risks: the NLCS among never-smoking women, and the NHS in the entire cohort ([@bib14]; [@bib34]). Although the NLCS and NHS studies did not evaluate the association between acrylamide intake and type-I EC specifically, about 80% of EC cases are thought to be type-I endometrioid tumours ([@bib2]); thus, the majority of the cases in the previous publications were likely type-I EC cases. Only the SMC study observed no associations between acrylamide intake and EC risk ([@bib19]), and this could be due to the smaller baseline ranges of acrylamide intake in that study. The median acrylamide intake for the reference group in the SMC was 16.9 *μ*g per day, and for the highest intake category was 32.5 *μ*g per day, whereas in EPIC, the median for the reference group was 9.3 *μ*g per day, and for the highest intake category was 44.0 *μ*g per day. All three previous studies presented statistical models adjusted for OC use, but none reported analyses stratified by OC use.

Some evidence for an inverse association between the highest and lowest acrylamide quintiles and type-I EC risk was observed among women with a BMI \<25 kg m^−2^; however, neither the continuous variable for acrylamide intake (per 10 *μ*g per day) nor the LRT *P-*value were statistically significant. A suggestive increased risk for type-I EC was observed in women who reported never drinking alcohol at baseline when the continuous acrylamide variable was evaluated; nevertheless, this result was based on 103 type-I EC cases. Further, suggestive evidence for heterogeneity of the association between dietary acrylamide intake and type-I EC risk was also indicated by smoking status, and by menopausal status at baseline; nevertheless no dose-response trend was observed.

The strengths of our study are that EPIC is one of the largest prospective cohort studies on diet and cancer, and recall bias is unlikely because exposure and diet information were collected years before cancer diagnoses. The present study had more cases than the other three previously published studies (*n*=1382), and this allowed us to evaluate known type-I EC separately (*n*=627). The SMC study analysed 687 EC cases ([@bib19]), the NHS study analysed 484 EC cases ([@bib34]), and the NLCS study evaluated 221 ([@bib14]).

The present study had the following limitations: some food preparation techniques (e.g., cooking method) that could have contributed to the variability of total acrylamide intake were not assessed in all EPIC centres. In addition, the correlation coefficient between a single 24-h DR in EPIC, and acrylamide intake derived from food intake questionnaires was low: 0.17 ([@bib8]). This could indicate that a single 24-h DR may not be enough to accurately estimate the average acrylamide intake. Further, the EPIC acrylamide estimates might have been influenced by measurement error; however, all the analyses were adjusted for energy intake since in EPIC and in other populations, it has been observed that the validity of acrylamide estimates improved after energy intake adjustment ([@bib8]). Another limitation of our study is that 718 EC cases were not classified in any of the EC subtypes; however, as has been previously mentioned, a large proportion (≈80%) of endometrial carcinomas are thought to be type I ([@bib2]). Finally, it should to be kept in mind that several subgroups have been examined in this study; thus, some of the observed results might be due to chance.

In conclusion, the results of the present study indicate that there were no associations between dietary intake of acrylamide and risk of overall EC or type-I EC; nevertheless, women with elevated acrylamide intake (upper quintile median, 44 *μ*g per day) who both never smoked and never used OCs at baseline, were at higher risk of developing type-I EC relative to women with the lowest intakes. Additional studies with biomarkers of internal dose of acrylamide exposure are needed in order to better understand the associations observed.
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###### Estimated dietary intake of acrylamide and EC cases by country in the EPIC subcohort of women

  **Country**       **Cohort sample**   **Person-years**   **EC cases** ***N* (%)**   **Type-I cases** ***N* (%)**   **Type-II cases** ***N* (%)**   **Cases undefined by type** ***N* (%)**   **Acrylamide (*****μ*****g per day)** **Mean±s.d.**   **Acrylamide**[a](#t1-fn2){ref-type="fn"} (***μ*****g per day)** **Mean±s.d.**   **Acrylamide (*****μ*****g per kg body weight per day)** **Mean±s.d.**
  ----------------- ------------------- ------------------ -------------------------- ------------------------------ ------------------------------- ----------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------
  France            60 702              629 899            276 (20.0)                 79 (12.6)                      3 (8.1)                         194 (27.0)                                20.4±8.8                                              18.3±6.6                                                                         0.4±0.2
  Italy             27 760              310 816            132 (9.6)                  48 (7.7)                       1 (2.7)                         83 (11.6)                                 10.9±6.1                                              8.8±5.7                                                                          0.2±0.1
  Spain             22 783              275 042            102 (7.4)                  48 (7.7)                       3 (8.1)                         51 (7.1)                                  20.6±12.1                                             21.3±10.3                                                                        0.3±0.2
  United Kingdom    46 068              513 816            170 (12.3)                 74 (11.8)                      5 (13.5)                        91 (12.7)                                 33.1±15.3                                             33.4±13.1                                                                        0.5±0.3
  The Netherlands   22 140              260 499            107 (7.7)                  59 (9.4)                       5 (13.5)                        43 (6.0)                                  31.2±13.7                                             31.7±12.1                                                                        0.5±0.2
  Greece            13 967              136 097            18 (1.3)                   4 (0.6)                        1 (2.7)                         13 (1.8)                                  19.2±9.1                                              19.8±7.2                                                                         0.3±0.1
  Germany           23 321              231 579            82 (5.9)                   67 (10.7)                      4 (10.8)                        11 (1.5)                                  24.5±11.2                                             25.3±9.7                                                                         0.4±0.2
  Sweden            26 375              349 308            183 (13.2)                 1 (0.2)                        4 (10.8)                        178 (24.8)                                22.4±9.7                                              23.6±8.2                                                                         0.3±0.2
  Denmark           24 473              269 910            182 (13.2)                 140 (22.3)                     9 (24.3)                        33 (4.6)                                  35.6±11.7                                             35.5±10.2                                                                        0.5±0.2
  Norway            33 524              326 296            130 (9.4)                  107 (17.1)                     2 (5.4)                         21 (2.9)                                  17.9±6.5                                              20.6±5.8                                                                         0.3±0.1
  Total             301 113             3 303 262          1382                       627                            37                              718                                       23.7±13.0                                             23.7±12.0                                                                        0.4±0.2

Abbreviations: EC=endometrial cancer; EPIC=European Prospective Investigation into Cancer and Nutrition; s.d.=standard deviation.

Energy adjusted using the residual method.

###### Estimated total dietary intake of acrylamide (energy adjusted using the residual method) and covariates at baseline used in the analyses: EPIC subcohort (301 113 women)

                                                                      **Energy-adjusted acrylamide intake (*****μ*****g per day)**                                               
  ------------------------------------------------------------------ -------------------------------------------------------------- -------------- -------------- -------------- --------------
  Participants (*n*)                                                                             60 222                                 60 223         60 223         60 223         60 222
  Endometrial cancer cases (*n)*                                                                  277                                    271            298            250            286
  Type-I EC cases (*n)*                                                                           105                                    111            125            122            164
  Energy-adjusted acrylamide intake (median; *μ*g per day)                                        10.7                                   17.2           21.7           27.4           39.3
  Age (years)                                                                     51.1±8.4[a](#t2-fn2){ref-type="fn"}                  50.8±9.1       50.1±9.6      49.7±10.6      49.6±11.5
  Age at first menstrual period (years)[b](#t2-fn3){ref-type="fn"}                              12.8±1.5                               13.1±1.5       13.1±1.5       13.2±1.5       13.2±1.6
  Age at menopause (years)[b](#t2-fn3){ref-type="fn"}                                           49.3±4.4                               49.3±4.5       49.3±4.5       49.4±4.4       49.4±4.3
  **Menopausal status (%)**                                                                                                                                                      
   Premenopausal                                                                                  36.5                                  35.76           37.8          40.05          40.15
   Perimenopausal                                                                                18.16                                  20.55          19.68          16.51          12.92
   Postmenopausal[c](#t2-fn4){ref-type="fn"}                                                     45.34                                  43.69          42.52          43.44          46.93
  **Ever use of OCs (%)**                                                                                                                                                        
   Yes                                                                                           49.45                                   55.8          58.12          61.46          65.48
   Unknown                                                                                        0.65                                   2.51           4.53           4.04           1.8
  Duration of using OCs (years)[b](#t2-fn3){ref-type="fn"}                                      6.1±6.6                                7.4±7.2        7.9±7.4        8.4±7.5        8.7±7.5
  **Ever use of HRT (%)**                                                                                                                                                        
   Yes                                                                                           19.96                                  22.71          21.94          21.29          22.22
   Unknown                                                                                        3.25                                   6.69           9.09           9.33           6.37
  Duration of using HRT (years)[b](#t2-fn3){ref-type="fn"}                                      2.9±3.1                                3.4±3.3        3.6±3.6        3.9±4.2        4.2±4.6
  **Smoking status (%)**                                                                                                                                                         
   Never                                                                                         59.49                                  60.01          55.53          52.35          49.68
   Former                                                                                        19.45                                   20.8          22.71          23.88          25.15
   Current                                                                                       18.86                                  15.75          18.88          21.61          23.85
   Unknown                                                                                        2.2                                    3.44           2.88           2.16           1.31
  Cigarettes per day (smokers only)                                                             13.1±8.7                               12.5±7.7       12.8±7.5       13.2±7.6       14.0±7.8
  Time since quitting[d](#t2-fn5){ref-type="fn"} (years)                                        13.7±9.0                               15.0±9.6       14.8±9.8      14.9±10.1      14.9±10.5
  **Prevalent diabetes (%)**                                                                                                                                                     
   Yes                                                                                            2.67                                   2.42           2.0            1.65           1.61
   Unknown                                                                                        1.94                                   4.42           5.07           4.59           4.64
  **Alcohol**                                                                                                                                                                    
   Non-consumers (%)                                                                             22.56                                  19.08          16.49          13.51          10.24
   Consumers (g per day)                                                                        9.2±14.1                               7.2±10.9       6.6±10.1       7.6±10.8       8.5±10.9
  **Education (%)**                                                                                                                                                              
   Primary school completed                                                                      31.48                                  20.23          21.76          21.93          21.13
   Higher education[e](#t2-fn6){ref-type="fn"}                                                   22.57                                  25.92          23.91          23.56           21.5
   Unknown                                                                                        1.72                                   2.69           2.98           4.3            6.31
  **Physical activity (%)**                                                                                                                                                      
   Inactive                                                                                      28.99                                  21.35          19.13          18.26          17.44
   Active                                                                                         9.49                                   9.71          11.78          15.93          22.08
   Unknown                                                                                        7.09                                  18.22          19.71          12.13           4.29
  BMI (kg m^−2^)                                                                                25.1±4.5                               24.6±4.4       24.7±4.3       24.8±4.4       25.0±4.4
  WHR[b](#t2-fn3){ref-type="fn"}                                                                0.8±0.1                                0.8±0.1        0.8±0.1        0.8±0.1        0.8±0.1
  Energy (kcal)                                                                               2098.2±571.9                           1860.1±521.1   1810.3±515.9   1873.8±516.2   2027.5±523.3
  Total fats (g per day)                                                                       84.8±28.3                              74.5±26.3      70.9±25.8      72.6±25.9      78.3±26.4
  Carbohydrates (g per day)                                                                    224.5±74.2                             203.7±63.6      204±62.3      213.0±63.9     232.7±67.3
  Vegetables (g per day)                                                                      252.9±165.6                            232.3±146.5    203.1±133.6    198.8±129.8    204.5±127.7
  Coffee (ml per day)                                                                         123.6±129.9                            228.5±194.4    337.8±240.2    441.8±305.9    643.4±449.3
  Bread, crisp bread, and rusks (g per day)                                                    121.1±76.0                             114.9±65.9     115.7±66.1     116.6±67.4     124.2±69.1
  Potatoes (g per day)                                                                         48.6±46.2                              70.8±52.9      84.3±57.5      95.1±64.4      105.7±67.5
  Cakes and biscuits (g per day)                                                               34.8±37.6                              34.8±33.4      38.4±34.3      42.4±38.6      48.3±47.7

Abbreviations: BMI=body mass index; EC=endometrial cancer; EPIC=European Prospective Investigation into Cancer and Nutrition; HRT=hormonal replacement therapy; OCs=oral contraceptives; WHR=waist-to-hip ratio.

Mean±s.d.

Number of women missing the following; age at first menstrual period: 10 321; age at menopause: 201 651; duration of using OCs: 142 462; duration of using HRT: 278 012; number of cigarettes: 243 668; time since quitting smoking; 236 217; and WHR: 88 717.

Includes surgical menopause.

Only in former smokers.

Higher education includes any university degree or above.

###### Hazard ratios and 95% confidence intervals for the estimated dietary intake of acrylamide (energy-adjusted using the residual method) and EC risk in EPIC

                                                              **Energy-adjusted acrylamide intake (*****μ*****g per day)**                                                                                                      
  ---------------------------------------------------------- -------------------------------------------------------------- ------------ ------------------- ------------------- ------------------- ------------------- ------ ------
  **Final model -- overall EC**                                                                                                                                                                                                 
  *N* cases                                                                               1382                                  277              271                 298                 250                 286                 
  HR (95% CI)[b](#t3-fn3){ref-type="fn"}                                           0.98 (0.92--1.05)                         1.00 (ref)   1.05 (0.86--1.29)   1.11 (0.90--1.36)   0.88 (0.71--1.10)   0.98 (0.78--1.25)  0.53    
  **Cases diagnosed ⩾2 years after recruitment**                                                                                                                                                                                
  *N* cases                                                                               1186                                  240              217                 268                 215                 246                 
  HR (95% CI)[b](#t3-fn3){ref-type="fn"}                                           0.98 (0.91--1.05)                         1.00 (ref)   0.97 (0.78--1.20)   1.12 (0.89--1.39)   0.85 (0.67--1.08)   0.95 (0.74--1.23)  0.52    
  **Overall EC -- stratified analyses**                                                                                                                                                                                         
  **Smoking status**                                                                                                                                                                                                            
  Never smokers                                                                                                                                                                                                                  
  * N* cases                                                                              747                                   147              142                 153                 132                 173                 
  * *HR (95% CI)[c](#t3-fn4){ref-type="fn"}                                        0.97 (0.89--1.05)                         1.00 (ref)   1.03 (0.79--1.34)   1.04 (0.79--1.36)   0.82 (0.61--1.10)   1.01 (0.75--1.38)  0.90    
  Ever smokers[d](#t3-fn5){ref-type="fn"}                                                                                                                                                                                       0.20
  * N* cases                                                                              587                                   123              118                 135                 110                 101                 
  * *HR (95% CI)[c](#t3-fn4){ref-type="fn"}                                        0.98 (0.89--1.08)                         1.00 (ref)   1.08 (0.80--1.45)   1.23 (0.91--1.66)   0.96 (0.69--1.33)   0.86 (0.60--1.24)  0.23    
  **OC use**                                                                                                                                                                                                                    
  Non-OC users                                                                                                                                                                                                                   
  * N* cases                                                                              800                                   180              155                 165                 127                 173                 
  * *HR (95% CI)[e](#t3-fn6){ref-type="fn"}                                        1.03 (0.94--1.12)                         1.00 (ref)   1.07 (0.83--1.38)   1.09 (0.84--1.42)   0.83 (0.62--1.11)   1.17 (0.86--1.58)  0.51    
  OC users                                                                                                                                                                                                                      0.03
  * N* cases                                                                              547                                    94              111                 121                 117                 104                 
  * *HR (95% CI)[e](#t3-fn6){ref-type="fn"}                                        0.92 (0.83--1.02)                         1.00 (ref)   1.05 (0.76--1.46)   1.16 (0.83--1.61)   0.97 (0.68--1.39)   0.79 (0.53--1.15)  0.08    
  **Smoking status combined with OC use**                                                                                                                                                                                       
  Never smokers and non-OC users                                                                                                                                                                                                 
  * N* cases                                                                              477                                   106              90                  94                  75                  112                 
   HR (95% CI)[f](#t3-fn7){ref-type="fn"}                                          1.02 (0.92--1.13)                         1.00 (ref)   1.05 (0.76--1.44)   1.08 (0.77--1.50)   0.82 (0.57--1.18)   1.28 (0.88--1.85)  0.24    
  Ever smokers[d](#t3-fn5){ref-type="fn"} and non-OC users                                                                                                                                                                       
  * N* cases                                                                              299                                    68              58                  68                  47                  58                  
   HR (95% CI)[f](#t3-fn7){ref-type="fn"}                                          1.02 (0.89--1.17)                         1.00 (ref)   1.09 (0.73--1.65)   1.28 (0.84--1.95)   0.87 (0.55--1.39)   0.98 (0.60--1.60)  0.65    
  Never smokers and OC users                                                                                                                                                                                                    0.04
  * N* cases                                                                              253                                    39              49                  52                  54                  59                  
   HR (95% CI)[f](#t3-fn7){ref-type="fn"}                                          0.89 (0.77--1.03)                         1.00 (ref)   1.03 (0.64--1.67)   0.98 (0.60--1.61)   0.83 (0.50--1.40)   0.73 (0.42--1.26)  0.13    
  Ever smokers[d](#t3-fn5){ref-type="fn"} and OC users                                                                                                                                                                           
  * N* cases                                                                              277                                    54              58                  63                  60                  42                  
   HR (95% CI)[f](#t3-fn7){ref-type="fn"}                                          0.93 (0.80--1.08)                         1.00 (ref)   1.10 (0.71--1.69)   1.22 (0.78--1.90)   1.07 (0.67--1.71)   0.76 (0.44--1.30)  0.22    
  **Alcohol intake**                                                                                                                                                                                                            
  Never drinkers                                                                                                                                                                                                                 
  * N* cases                                                                              253                                    70              59                  38                  35                  51                  
   HR (95% CI)[b](#t3-fn3){ref-type="fn"}                                          1.06 (0.91--1.24)                         1.00 (ref)   0.95 (0.62--1.46)   0.72 (0.44--1.18)   0.59 (0.35--1.00)   1.03 (0.60--1.76)  0.76    
  Ever drinkers                                                                                                                                                                                                                 0.07
  * N* cases                                                                              1129                                  207              212                 260                 215                 235                 
   HR (95% CI)[b](#t3-fn3){ref-type="fn"}                                          0.97 (0.90--1.04)                         1.00 (ref)   1.10 (0.87--1.39)   1.27 (1.00--1.61)   0.96 (0.75--1.24)   1.01 (0.77--1.32)  0.54    
  **Body mass index**                                                                                                                                                                                                           
  \<25 kg m^−2^                                                                                                                                                                                                                  
  * N* cases                                                                                                                                                                                                                     
   HR (95% CI)[g](#t3-fn8){ref-type="fn"}                                          1.01 (0.91--1.12)                         1.00 (ref)   0.94 (0.70--1.27)   1.13 (0.83--1.53)   0.92 (0.67--1.28)   0.93 (0.64--1.35)  0.68    
  ⩾25 kg m^−2^                                                                                                                                                                                                                  0.96
  * N* cases                                                                                                                                                                                                                     
   HR (95% CI)[g](#t3-fn8){ref-type="fn"}                                          0.99 (0.90--1.08)                         1.00 (ref)   1.29 (0.96--1.73)   1.21 (0.89--1.64)   0.94 (0.68--1.31)   1.12 (0.79--1.57)  0.89    
  **Menopausal status**                                                                                                                                                                                                         
  Premenopausal                                                                                                                                                                                                                  
  * N* cases                                                                              253                                    67              54                  52                  45                  35                  
   HR (95% CI)[h](#t3-fn9){ref-type="fn"}                                          0.88 (0.74--1.04)                         1.00 (ref)   1.12 (0.72--1.74)   1.12 (0.70--1.78)   1.00 (0.61--1.64)   0.68 (0.37--1.22)  0.17    
  Perimenopausal                                                                                                                                                                                                                0.05
  * N* cases                                                                              268                                    51              56                  73                  44                  44                  
   HR (95% CI)[h](#t3-fn9){ref-type="fn"}                                          1.05 (0.89--1.23)                         1.00 (ref)   1.08 (0.69--1.70)   1.29 (0.82--2.04)   0.83 (0.50--1.39)   1.18 (0.67--2.10)  0.90    
  Postmenopausal[i](#t3-fn10){ref-type="fn"}                                                                                                                                                                                     
  * N* cases                                                                              861                                   159              161                 173                 161                 207                 
   HR (95% CI)[h](#t3-fn9){ref-type="fn"}                                          1.01 (0.93--1.10)                         1.00 (ref)   1.05 (0.80--1.38)   1.06 (0.80--1.40)   0.84 (0.62--1.13)   1.03 (0.76--1.40)  0.99    

Abbreviations: BMI=body mass index; CI=confidence interval; EC=endometrial cancer; EPIC=European Prospective Investigation into Cancer and Nutrition; HR=hazards ratio; HRT=hormonal replacement therapy; LRT=likelihood ratio test; OCs=oral contraceptives.

All LRT *P*-values for effect measure modification are based on the continuous acrylamide intake variable (per 10 μg per day).

Stratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment, centre, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at menopause, parity, and age at menarche.

Ever smokers: former and current smokers.

Stratified by age at recruitment, centre, smoking status, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at menopause, parity and age at menarche.

Stratified by age at recruitment, centre, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), prevalent diabetes, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, parity, and age at menarche.

Includes surgical menopause.

###### Hazard ratios and 95% confidence intervals for the estimated dietary intake of acrylamide (energy-adjusted using the residual method) and type-I endometrial cancer risk in EPIC

                                                             **Energy-adjusted acrylamide intake (*****μ*****g per day)**                                                                                                       
  ---------------------------------------------------------- -------------------------------------------------------------- ------------ ------------------- ------------------- ------------------- ------------------- ------ ------
  **Final model -- Type I**                                                                                                                                                                                                     
  *N* cases                                                  627                                                            105          111                 125                 122                 164                         
  HR (95% CI)[b](#t4-fn3){ref-type="fn"}                     0.98 (0.90--1.07)                                              1.00 (ref)   1.00 (0.74--1.35)   1.04 (0.77--1.42)   0.87 (0.63--1.21)   0.97 (0.69--1.36)   0.79    
  **Cases diagnosed ⩾2 years after recruitment**                                                                                                                                                                                
  *N* cases                                                  556                                                            98           93                  117                 107                 141                         
  HR (95% CI)[b](#t4-fn3){ref-type="fn"}                     0.96 (0.87--1.06)                                              1.00 (ref)   0.89 (0.65--1.23)   1.04 (0.76--1.43)   0.84 (0.60--1.19)   0.93 (0.65--1.32)   0.75    
  **Type I -- stratified analyses**                                                                                                                                                                                             
  **Smoking status**                                                                                                                                                                                                            
  Never smokers                                                                                                                                                                                                                  
  * N* cases                                                 350                                                            56           54                  67                  69                  104                         
  * *HR (95% CI)[c](#t4-fn4){ref-type="fn"}                  1.06 (0.95--1.19)                                              1.00 (ref)   0.97 (0.63--1.48)   1.14 (0.74--1.74)   0.97 (0.62--1.51)   1.25 (0.79--1.98)   0.21    
  Ever smokers[d](#t4-fn5){ref-type="fn"}                                                                                                                                                                                       0.01
  * N* cases                                                 257                                                            44           51                  55                  50                  57                          
  * *HR (95% CI)[c](#t4-fn4){ref-type="fn"}                  0.90 (0.78--1.03)                                              1.00 (ref)   1.02 (0.64--1.63)   1.00 (0.62--1.62)   0.80 (0.48--1.34)   0.70 (0.41--1.19)   0.09    
  **OC use**                                                                                                                                                                                                                    
  Non-OC users                                                                                                                                                                                                                   
  * N* cases                                                 347                                                            65           56                  65                  58                  103                         
   HR (95% CI)[e](#t4-fn6){ref-type="fn"}                    1.10 (0.99--1.23)                                              1.00 (ref)   0.96 (0.64--1.45)   1.09 (0.71--1.67)   0.90 (0.57--1.42)   1.40 (0.89--2.22)   0.06    
  OC users                                                                                                                                                                                                                      0.01
  * N* cases                                                 273                                                            39           54                  59                  63                  58                          
   HR (95% CI)[e](#t4-fn6){ref-type="fn"}                    0.83 (0.71--0.95)                                              1.00 (ref)   0.97 (0.62--1.51)   0.93 (0.59--1.47)   0.79 (0.49--1.28)   0.57 (0.34--0.96)   0.01    
  **Smoking status combined with OC use**                                                                                                                                                                                       
  Never smokers and non-OC users                                                                                                                                                                                                 
  * N* cases                                                 203                                                            35           29                  36                  35                  68                          
   HR (95% CI)[f](#t4-fn7){ref-type="fn"}                    1.17 (1.02--1.34)                                              1.00 (ref)   1.03 (0.58--1.81)   1.28 (0.72--2.27)   1.12 (0.61--2.06)   1.97 (1.08--3.62)   0.01    
  Ever smokers[d](#t4-fn5){ref-type="fn"} and non-OC users                                                                                                                                                                       
  * N* cases                                                 134                                                            26           25                  27                  21                  35                          
   HR (95% CI)[f](#t4-fn7){ref-type="fn"}                    1.04 (0.86--1.26)                                              1.00 (ref)   0.99 (0.51--1.91)   0.99 (0.50--1.98)   0.76 (0.36--1.62)   1.01 (0.47--2.19)   0.98    
  Never smokers and OC users                                                                                                                                                                                                    0.01
  * N* cases                                                 145                                                            20           25                  31                  33                  36                          
   HR (95% CI)[f](#t4-fn7){ref-type="fn"}                    0.89 (0.73--1.09)                                              1.00 (ref)   0.76 (0.40--1.45)   0.83 (0.44--1.59)   0.68 (0.35--1.35)   0.59 (0.29--1.21)   0.17    
  Ever smokers[d](#t4-fn5){ref-type="fn"} and OC users                                                                                                                                                                           
  * N* cases                                                 120                                                            18           25                  27                  29                  21                          
   HR (95% CI)[f](#t4-fn7){ref-type="fn"}                    0.75 (0.60--0.94)                                              1.00 (ref)   1.02 (0.52--1.99)   1.00 (0.50--1.98)   0.84 (0.41--1.72)   0.45 (0.20--1.00)   0.02    
  **Alcohol intake**                                                                                                                                                                                                            
  Never drinkers                                                                                                                                                                                                                 
  * N* cases                                                 103                                                            28           19                  13                  17                  26                          
   HR (95% CI)[b](#t4-fn3){ref-type="fn"}                    1.23 (1.02--1.47)                                              1.00 (ref)   0.76 (0.40--1.44)   0.61 (0.29--1.28)   0.93 (0.46--1.89)   1.77 (0.86--3.64)   0.07    
  Ever drinkers                                                                                                                                                                                                                 0.01
  * N* cases                                                 524                                                            77           92                  112                 105                 138                         
   HR (95% CI)[b](#t4-fn3){ref-type="fn"}                    0.93 (0.85--1.03)                                              1.00 (ref)   1.09 (0.77--1.54)   1.19 (0.83--1.69)   0.90 (0.61--1.31)   0.91 (0.62--1.35)   0.30    
  **Body mass index**                                                                                                                                                                                                           
  \<25 kg m^−2^                                                                                                                                                                                                                  
  * N* cases                                                 256                                                            43           48                  62                  53                  50                          
   HR (95% CI)[g](#t4-fn8){ref-type="fn"}                    0.86 (0.74--1.00)                                              1.00 (ref)   0.88 (0.56--1.38)   1.11 (0.71--1.73)   0.78 (0.48--1.27)   0.56 (0.33--0.96)   0.02    
  ⩾25 kg m^−2^                                                                                                                                                                                                                  0.28
  * N* cases                                                 371                                                            62           63                  63                  69                  114                         
   HR (95% CI)[g](#t4-fn8){ref-type="fn"}                    1.06 (0.95--1.18)                                              1.00 (ref)   1.12 (0.75--1.69)   0.99 (0.64--1.52)   0.92 (0.59--1.44)   1.34 (0.85--2.10)   0.12    
  **Menopausal status**                                                                                                                                                                                                         
  Premenopausal                                                                                                                                                                                                                  
  * N* cases                                                 120                                                            28           25                  26                  24                  17                          
   HR (95% CI)[h](#t4-fn9){ref-type="fn"}                    0.78 (0.62--0.99)                                              1.00 (ref)   0.89 (0.48--1.64)   0.91 (0.49--1.71)   0.78 (0.40--1.53)   0.52 (0.24--1.13)   0.09    
  Perimenopausal                                                                                                                                                                                                                0.01
  * N* cases                                                 120                                                            24           25                  32                  20                  19                          
   HR (95% CI)[h](#t4-fn9){ref-type="fn"}                    0.88 (0.70--1.12)                                              1.00 (ref)   0.77 (0.41--1.43)   0.91 (0.49--1.68)   0.67 (0.33--1.36)   0.59 (0.26--1.31)   0.22    
  Postmenopausal[i](#t4-fn10){ref-type="fn"}                                                                                                                                                                                     
  * N* cases                                                 387                                                            53           61                  67                  78                  128                         
   HR (95% CI)[h](#t4-fn9){ref-type="fn"}                    1.07 (0.96--1.18)                                              1.00 (ref)   1.24 (0.81--1.89)   1.25 (0.81--1.95)   1.09 (0.69--1.72)   1.39 (0.88--2.20)   0.17    

Abbreviations: BMI=body mass index; CI=confidence interval; EPIC=European Prospective Investigation into Cancer and Nutrition; HR=hazards ratio; HRT=hormonal replacement therapy; LRT=likelihood ratio test; OCs=oral contraceptives.

All LRT *P*-values for effect measure modification are based on the continuous acrylamide intake variable (per 10 *μ*g per day).

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, OC use, HRT use, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, OC use, HRT use, menopause status combined with age at menopause, parity, and age at menarche.

Ever smokers: former and current smokers.

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, HRT use, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, HRT use, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), smoking status, prevalent diabetes, OC use, HRT use, menopause status combined with age at menopause, parity, and age at menarche.

Stratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, OC use, HRT use, parity, and age at menarche.

Includes surgical menopause.
